NZ598482A - Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations - Google Patents

Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations

Info

Publication number
NZ598482A
NZ598482A NZ598482A NZ59848210A NZ598482A NZ 598482 A NZ598482 A NZ 598482A NZ 598482 A NZ598482 A NZ 598482A NZ 59848210 A NZ59848210 A NZ 59848210A NZ 598482 A NZ598482 A NZ 598482A
Authority
NZ
New Zealand
Prior art keywords
amino
triazoles
preparing
processes
novel compositions
Prior art date
Application number
NZ598482A
Other languages
English (en)
Inventor
Rashida A Karmali
Original Assignee
Tactical Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43648255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ598482(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tactical Therapeutics Inc filed Critical Tactical Therapeutics Inc
Publication of NZ598482A publication Critical patent/NZ598482A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ598482A 2009-09-04 2010-09-03 Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations NZ598482A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58444809A 2009-09-04 2009-09-04
PCT/US2010/002430 WO2011028288A1 (en) 2009-09-04 2010-09-03 Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
US12/807,415 US8377973B2 (en) 2009-09-04 2010-09-03 Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations

Publications (1)

Publication Number Publication Date
NZ598482A true NZ598482A (en) 2014-05-30

Family

ID=43648255

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ598482A NZ598482A (en) 2009-09-04 2010-09-03 Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
NZ624636A NZ624636A (en) 2009-09-04 2013-02-27 Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ624636A NZ624636A (en) 2009-09-04 2013-02-27 Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations

Country Status (19)

Country Link
US (1) US8377973B2 (https=)
EP (2) EP2473051B1 (https=)
JP (4) JP2013503861A (https=)
KR (1) KR101597338B1 (https=)
CN (2) CN104817507A (https=)
AP (1) AP3345A (https=)
AU (1) AU2010290049B2 (https=)
BR (1) BR112012004539A2 (https=)
CA (1) CA2772075C (https=)
CL (1) CL2012000582A1 (https=)
HK (1) HK1212983A1 (https=)
IL (1) IL218430A0 (https=)
MX (2) MX2012002730A (https=)
MY (1) MY159430A (https=)
NZ (2) NZ598482A (https=)
PH (1) PH12015502088A1 (https=)
RU (1) RU2594155C2 (https=)
SG (1) SG178413A1 (https=)
WO (1) WO2011028288A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877785B2 (en) * 2009-09-04 2014-11-04 Tactical Therapeutics Inc Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate
US9089570B2 (en) * 2010-09-03 2015-07-28 Tactical Therapeutics Inc Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
US10378059B2 (en) * 2013-08-02 2019-08-13 Tactical Therapeutics, Inc. Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
KR102623581B1 (ko) * 2016-07-18 2024-01-11 일동제약(주) 항바이러스성 약물의 오로트산염, 이의 제조 방법 및 상기 염을 포함하는 약제학적 조성물
CN112083109B (zh) * 2019-07-08 2021-05-25 广东银珠医药科技有限公司 羧胺三唑杂质及其制备方法和检测方法
US20220168276A1 (en) * 2020-08-05 2022-06-02 Tactical Therapeotics Inc. Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate
CN112358451B (zh) * 2021-01-11 2021-04-13 广东银珠医药科技有限公司 羧胺三唑的合成方法
CN113582935A (zh) * 2021-08-27 2021-11-02 中国医学科学院放射医学研究所 一种炎症小体核苷酸结合寡聚化结构域样受体蛋白3抑制剂及其制备方法和应用
CN113620892B (zh) * 2021-10-12 2022-02-22 广东银珠医药科技有限公司 羧胺三唑单晶、制备方法及其组合物和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2415740C2 (de) 1974-04-01 1983-12-01 Servomed Arznei GmbH & Co Pharma KG, 8000 München Verwendung von Orotsäure bei der analgetischen Behandlung mit Dextropropoxyphen, Natriumsalicylat oder Metamizol
US4590201A (en) 1984-02-02 1986-05-20 Merck & Co., Inc. 5-amino or substituted amino 1,2,3-triazoles
US4847257A (en) * 1987-08-20 1989-07-11 Merck & Co., Inc. 5-Amino or substituted amino 1,2,3,-triazoles useful as antiproliferative agents
JPH0356417A (ja) * 1989-05-08 1991-03-12 Merck & Co Inc 抗転移剤として有用な５―アミノ又は置換アミノ１，２，３―トリアゾール類
US5132315A (en) * 1989-05-19 1992-07-21 The United States Of America As Represented By The Department Of Health And Human Services Therapeutic application of an anti-invasive compound
US5359078A (en) * 1989-05-19 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Signal transduction inhibitor compounds
CA2575902C (en) 1995-07-21 2010-06-08 Tactical Therapeutics Inc Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
TW403740B (en) * 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
WO2005116024A1 (en) * 2004-05-25 2005-12-08 Astrazeneca Ab 3- (4- (2-dihydroisoxazol-3-ylpyridin-5-yl) phenyl) -5-triazol-1-ylmethyloxazolidin-2-one derivaives as mao inhibitors for the treatment of bacterial infections
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
KR20100059919A (ko) * 2007-09-24 2010-06-04 코멘티스, 인코포레이티드 치료를 위한 베타-세크레타제 억제제로서 (3-히드록시-4-아미노-부탄-2일)-3-(2-티아졸-2-일-피롤리딘-1-카르보닐) 벤즈아미드 유도체 및 관련 화합물
US20150323994A1 (en) * 2014-05-07 2015-11-12 Immersion Corporation Dynamic haptic effect modification
JP2017150532A (ja) * 2016-02-23 2017-08-31 Ntn株式会社 回転伝達装置

Also Published As

Publication number Publication date
AU2010290049A1 (en) 2012-03-29
EP2473051A4 (en) 2013-03-13
EP2473051A1 (en) 2012-07-11
IL218430A0 (en) 2012-04-30
EP2473051B1 (en) 2016-02-10
WO2011028288A1 (en) 2011-03-10
CN104817507A (zh) 2015-08-05
AP2012006187A0 (en) 2012-04-30
JP2020105178A (ja) 2020-07-09
CN102595904A (zh) 2012-07-18
JP2013503861A (ja) 2013-02-04
AU2010290049B2 (en) 2013-09-19
CA2772075C (en) 2017-02-28
EP2963023A1 (en) 2016-01-06
CA2772075A1 (en) 2011-03-10
JP2017203038A (ja) 2017-11-16
HK1212983A1 (zh) 2016-06-24
CL2012000582A1 (es) 2012-09-07
SG178413A1 (en) 2012-03-29
PH12015502088B1 (en) 2017-03-22
RU2012111454A (ru) 2013-10-10
RU2594155C2 (ru) 2016-08-10
MY159430A (en) 2017-01-13
MX2012002730A (es) 2012-07-20
KR20120092587A (ko) 2012-08-21
US8377973B2 (en) 2013-02-19
BR112012004539A2 (pt) 2020-09-15
JP2016026213A (ja) 2016-02-12
MX355198B (es) 2018-04-06
US20110060142A1 (en) 2011-03-10
PH12015502088A1 (en) 2017-03-22
CN102595904B (zh) 2016-08-03
EP2963023B1 (en) 2018-04-18
AP3345A (en) 2015-07-31
KR101597338B1 (ko) 2016-02-24
NZ624636A (en) 2014-06-27

Similar Documents

Publication Publication Date Title
NZ598482A (en) Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
WO2011031554A3 (en) Heterocyclic compounds as janus kinase inhibitors
WO2008094909A3 (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
EP4328223A3 (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
JP2014520898A5 (https=)
MX2009008338A (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
NZ701440A (en) Pyrazole derivatives as jak inhibitors
MX2012001420A (es) Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus.
SG170739A1 (en) Iap bir domain binding compounds
WO2010026436A3 (en) 1,3, 4, 6, 7, 11b-hexahydro-benzo[alpha]quinolizines for the treatment of hyperkinetic movement and related disorders
WO2011079230A3 (en) Heterocyclic compounds as janus kinase inhibitors
MX2009007482A (es) Agentes antiparasitarios.
MX2010004176A (es) Derivado de triazol 1,3,5-trisustituido.
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
WO2006119400A3 (en) Substituted 4,5-dihydro-1,2,4-triazin-6-ones, 1,2,4-trianzin-6-ones, and their use as fungicides
GEP20125547B (en) (aza) indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor
EP1717235A3 (en) Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
EA201100696A1 (ru) 1-(арилсульфонил)-4-(пиперазин-1-ил)-1h-бензимидазолы в качестве лигандов 5-гидрокситриптамина-6
IL185410A0 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease
WO2008011113A3 (en) Thiadiazolidinone derivatives
UY37222A (es) PROCEDIMIENTO PARA LA PREPARACIÓN DE DERIVADOS DE 1-FENILO-1,2,4-TRIAZOL SUSTITUIDOS POR 5-HIdroxIalQUILO
WO2010140139A3 (en) Crystalline forms of 6-(1h- imadazol- 1-yl) -2-phenylquinazoline
WO2007012972A3 (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
IL177315A0 (en) Process for the preparation of substituted triazole compounds

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 03 SEP 2017 BY PIPERS

Effective date: 20141113

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 SEP 2018 BY PIPERS

Effective date: 20170719

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 SEP 2019 BY PIPERS

Effective date: 20180727

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 SEP 2020 BY COMPUTER PACKAGES INC

Effective date: 20190820

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 SEP 2021 BY COMPUTER PACKAGES INC

Effective date: 20200818

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 SEP 2022 BY COMPUTER PACKAGES INC

Effective date: 20210817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 SEP 2023 BY COMPUTER PACKAGES INC

Effective date: 20220817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 SEP 2024 BY COMPUTER PACKAGES INC

Effective date: 20230817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 SEP 2025 BY COMPUTER PACKAGES INC

Effective date: 20240817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 SEP 2026 BY COMPUTER PACKAGES INC

Effective date: 20250817